Becton Dickinson (BDX) announced a strategic collaboration with the Institute for Immunology and Immune Health at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson price target raised to $210 from $202 at RBC Capital
- Becton Dickinson announces expansion of BD MAX System menu
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Unusually active option classes on open December 4th
- Becton Dickinson, ChemoGLO announce strategic collaboration